impact factor
logo
 

Clinical aspects

 

Clinical, autoimmune, and psychiatric parameters correlate with sleep disturbance in patients with systemic sclerosis and rheumatoid arthritis


1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11

 

  1. Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Messina, Italy. gianbagnato@gmail.com
  2. Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Messina, Italy.
  3. Division of Psychiatry, Department of Neuroscience, University of Messina, Italy.
  4. Division of Rheumatology, Department of Internal Medicine, University of Louisville, Kentucky, USA.
  5. Division of Rheumatology, Department of Internal Medicine, University of Louisville, Kentucky, USA.
  6. Division of Psychiatry, Department of Neuroscience, University of Messina, Italy.
  7. Division of Psychiatry, Department of Neuroscience, University of Messina, Italy.
  8. Division of Psychiatry, Department of Neuroscience, University of Messina, Italy.
  9. Division of Psychiatry, Department of Neuroscience, University of Messina, Italy.
  10. Division of Psychiatry, Department of Neuroscience, University of Messina, Italy.
  11. Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Messina, Italy.

CER8772
2016 Vol.34, N°5 ,Suppl.100
PI 0049, PF 0055
Clinical aspects

Free to view
(click on article PDF icon to read the article)

PMID: 27192425 [PubMed]

Received: 09/07/2015
Accepted : 07/10/2015
In Press: 10/05/2016
Published: 13/10/2016

Abstract

OBJECTIVES:
Sleep disturbance is an important contributor to poor quality of life in rheumatic disorders. This study aims to test whether clinical, autoimmune and psychological factors are associated with sleep disturbance in systemic sclerosis (SSc) compared to rheumatoid arthritis (RA) patients and controls.
METHODS:
101 female subjects (SSc=33, RA=34, healthy controls=34) participated in this observational, cross-sectional, parallel group study. Sleep disturbance was assessed with the Pittsburgh Sleep Quality Index (PSQI). Other assessments included the visual analogue scale (VAS) for pain, 36-item Short-Form Health Survey (SF-36), Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI). Clinical parameters, therapeutic regimen, and serologic status were recorded.
RESULTS:
In SSc patients, PSQI scores were higher than in RA patients and controls. Linear regression analysis showed that in SSc patients PSQI scores was associated with BDI, disease duration, modified Rodnan skin score and VAS, while DAS28 and BDI were associated with PSQI scores in RA patients. Anti-Scl70 and ANA positive SSc patients showed higher PSQI scores compared to those ANA positive only, while no differences were observed in RA patients classified according to rheumatoid factor positivity. SSc patients treated with immunosuppressants had lower PSQI scores compared to those not on therapy, whereas only corticosteroid treatment was significantly associated with higher PSQI scores in RA patients. RA patients with disease activity higher than moderate (DAS28≥3.2) had higher PSQI scores than those with lower than moderate (DAS28<3.2).
CONCLUSIONS:
Longitudinal studies are needed to identify disease-specific patterns associated with sleep disturbances and the influence on sleep function induced by immunosuppressive therapy among rheumatic patients.

Rheumatology Article